# Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

> **NCT07298148** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 28 (estimated)

## Conditions studied

- NSCLC Stage IV
- EGFR Positive Non-small Cell Lung Cancer
- EGFR-TKI Sensitizing Mutation

## Interventions

- **DRUG:** Firmonertinib 160mg

## Key facts

- **NCT ID:** NCT07298148
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298148, "Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07298148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*